Skip to main content

Table 2 Summary of changes in MSTCQ scores from Week 4 to 12 in the intent-to-treat population (n = 119)

From: Patient adherence to and tolerability of self-administered interferon β-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study

Time point

ISR*

FLS*

GSE†

Week 4 (n = 115)

   

   Mean (SD)

13.2 (4.02)

13.4 (4.56)

6.8 (3.16)

   Median (range)

13 (4-19)

13 (6-20)

6 (3-15)

Week 8 (n = 109)

   

   Mean (SD)

13.4 (3.64)

12.9 (4.10)

7.5 (3.16)

   Median (range)

13.5 (6-20)

12 (5-20)

8 (3-15)

Week 12 (n = 104)

   

   Mean (SD)

13.1 (3.39)

12.2 (4.30)

7.6 (3.05)

   Median (range)

13 (6-20)

11 (5-20)

8 (3-15)

p-value‡

0.902

0.022

0.002

  1. *Range: 1 (mild) to 20 (severe)
  2. †Range: 1 (poor treatment satisfaction) to 15 (excellent treatment satisfaction)
  3. ‡Repeated measures analysis of variance
  4. FLS 'flu-like' symptoms, GSE global side effects, ISR injection-site reactions; MSTCQ Multiple Sclerosis Treatment Concern Questionnaire, SD standard deviation
Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us